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“The measles had not prevailed on the Faroes since 1781; they broke out
early in April, 1846.) of the 7,782 inhabitants, about 6,000 were taken
with measles) 225 persons in all died) of the many old people still living
on the Faroes who had had the measles in 1781, not one) was attacked
the second time.”
[P. L. Panum, Observations Made during the Epidemic of Measles on the
Faroe Islands in the Year 1846]
The Faroe Islands measles outbreak described above is
of interest to geneticists in several regards:Why did some
people survive and some die? Why was the case fatality
rate so high? Why was the protective effect of prior
exposure so high? Understanding the genetic influences
on the phenotypes of protective and nonprotective an-
tibody responses provides a unique window to under-
stand the variability in host response to pathogens.
Infectious diseases have been postulated to be one of
the main forces of natural selection, shaping the genetic
constitution of man (Haldane 1949). Disease suscepti-
bility, resistance, and progression are influenced by HLA
genes (Bodmer 1996). For example, in Brazilian Amazon
tribes, Black et. al. (1977) explored reasons for the pro-
nounced susceptibility of these peoples to measles. The
major finding was a high degree of HLA homozygosity
in these virgin populations. Black et al. speculated that,
because of the high rate of homozygosity, HLA poly-
morphisms were restricted, and hence the range of im-
mune-response genes might be similarly restricted. The
deficiency of HLA homozygotes in other populations
studied has also been hypothesized to be caused by se-
lection against homozygotes by infectious diseases (Hed-
rick 1990).
It now appears that the HLA haplotype is one crucial
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determinant of immune response, but other factors that
participate in the processing of antigens and their display
on antigen-processing cells (APCs) also contribute to
susceptibility to viral infections. Although studies of im-
mune response to wild-virus infection are difficult and
depend on the ability to study subjects in proximity to
their infection, this limitation can be overcome by using
vaccines to probe the immunogenetic determinants of
immune responsiveness. Measles immunization results
in the delivery of a live, attenuated virus that undergoes
limited in vivo replication causing attenuated “infec-
tion,” inducing immune responses without disease.
Hence, live-measles immunization is an excellent model
with which to study the spectrum of host immune re-
sponses to the most transmissible disease known toman.
We have used the antibody response to live-measles
vaccine as a probe with which to examine systematically
the influence of specific HLA and other genes on anti-
body response. The advantage of this model is that sub-
jects can be immunized at any time, with little risk, and
under defined conditions. Knowledge of the immuno-
genetic factors related to vaccine response may provide
clues about the mechanisms of host defense to patho-
gens, leading to the design of novel vaccines, as well as
helping to identify individuals at risk for aberrant re-
sponses to infection or vaccines. This brief review will
highlight current research and directions for future in-
vestigation into the immunogenetic determinants of
host-pathogen/host-vaccine response.
Vaccine Response as a Marker of Disease
Susceptibility
Postimmunization antibody response can be used as
a marker of disease susceptibility. For example, the level
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of antibody response after hepatitis B immunization pre-
dicts susceptibility to disease on exposure (Ellis 1993).
In studies of measles, postimmunization measles anti-
body in the “low positive” range did not protect against
clinical measles when subjects were exposed to the wild
measles virus, whereas high levels were protective (Chen
et al. 1990). Furthermore, nonresponders to a single dose
of measles vaccine who demonstrated an antibody re-
sponse only after a second immunization were still six
times more likely than were responders to a single dose
of measles vaccine to develop measles on exposure to
wild virus (Mathias et al. 1989). Others examined “poor
responders,” who were reimmunized and developed
poor or low-level antibody responses only to lose de-
tectable antibody and develop measles on exposure 2–5
years later. They concluded that there is a strong cor-
relation between low antibody levels after a single dose
of vaccine and high susceptibility to infection with ex-
posure (Deseda-Tous et al. 1978).
The Role of the HLA Genes in Vaccine Immune
Response
Genetic factors, such as the HLA genes, and their in-
teraction with other factors (host, environmental, etc.)
are increasingly recognized as playing a significant role
in disease susceptibility, resistance, and progression
(Bodmer 1996; Detels et al. 1996; Singh et al. 1997).
The HLA genes encode the HLA antigens expressed on
antigen-presenting cells. These glycoproteins provide the
context in which processed antigenic peptides are pre-
sented to T cells and, hence, determine the ability of the
individual to respond immunologically to endogenous
and exogenous antigens. Therefore, the ability of an in-
dividual to respond to viral infection (or vaccination) by
antibody production is, in part, under the control of the
immune-response genes within the HLA complex on the
short arm of human chromosome 6.
Once in the cell, measles proteins are processed into
smaller antigenic peptides. Both the endogenous and ex-
ogenous antigen-processing pathways are important in
the development of antibody to measles (Malnati et al.
1992; Leopardi et al. 1993). Classically, in the endog-
enous pathway, cytosolic proteins are processed into
smaller antigenic peptides that are translocated, via the
transporters associated with antigen processing (TAP
proteins), into the endoplasmic reticulum (ER; Andro-
lewicz et al. 1993; Townsend and Trowsdale 1993).
There, peptides bind to class I HLA and the stable an-
tigen: class I HLA complexes transit the secretory path-
way and reach the cell surface. Because they serve as
selective peptide transporters, the TAP proteins regulate
which antigens are available for presentation to CD8
T cells and function as mediators of cellular immune
responses. In contrast, the exogenous pathway involves
endocytosis of antigens; the proteolytic processing of
these antigens and their binding to class II HLA mole-
cules occur within an acidic endosomal compartment.
Hence, the exogenous pathway, as classically defined,
does not require the peptide to cross a cellular lipid bi-
layer and so is TAP independent. Once formed, the an-
tigen–class II HLA complex is transported to the cell
surface for presentation to CD4 T cells.
The recognition that the host immune response is re-
lated to antigen processing and presentation is crucial
to the design of vaccines with adequate epitope for-
mation, and it suggests several possible mechanisms by
which genetic variations could lead to poor antibody
responses in some individuals. For instance, differences
in the expression (quantitative or otherwise) of major
histocompatibility complex (MHC) molecules on cell
membranes could influence immune response. Alterna-
tively, as discussed below, antigen-processing cells
(APCs) might be unable to form functional associations
between specific foreign antigens and HLA molecules.
TAP Genes: Function and Variation
The TAP genes were discovered in 1990 (Deverson et
al. 1990; Spies et al. 1990; Trowsdale et al. 1990), and
the genomic sequence of both TAP genes has been de-
termined. The two TAP genes identified thus far, TAP1
and TAP2, are physically situated within the class II HLA
gene cluster on the short arm of human chromosome 6,
within the DP–DQ interval. The TAP genes encode a
heterodimeric complex within the ER membrane and
show homology to the ATP-binding cassette superfamily
of transporters.
The TAP genes are polymorphic, with variant amino
acids in the membrane-spanning and ATP-binding cas-
sette domains (Quadri et al. 1995). Four alleles of the
TAP1 gene (two polymorphic sites at positions 333 and
637) and eight alleles of the TAP2 gene (four polymor-
phic sites at amino acid positions 379, 565, 665, and
687) have been identified, to date (Powis et al. 1993;
Szafer et al. 1994), with evidence for other rare TAP2
alleles (Aoki et al. 1993). Even with this moderate degree
of polymorphism (as compared with the extreme vari-
ability seen in the class I and II HLA loci), TAP genes
may contribute to a much greater degree of variation in
selective antigen transport at the level of the actual func-
tional transporter. In part, this may be due to the very
early and crucial step in the antigen-processing pathway
in which TAP gene products act, “magnifying” the im-
pact of the polymorphism of these genes. We and others
hypothesize that polymorphisms of TAP genes can re-
strict the peptides that are bound and then presented
(Neefjes et al. 1993, 1995; Shepherd et al. 1993; Hill
and Ploegh 1995) and that this restriction can occur
independent of linkage with other class II molecules
Poland: Ecogenetics ’98 217
(Heemels and Ploegh 1994; Barron et al. 1995; Mom-
burg et al. 1995; Savage et al. 1995).
Measles-Antigen Processing
The measles virus carries a spherical, single-stranded
RNA-based genome that encodes at least six structural
proteins (hemagglutinin protein [H], phosphoprotein,
nucleoprotein [N], fusion glycoprotein [F], matrix pro-
tein, and large protein). When measles virus binds to the
CD46 receptor of cell surfaces, measles envelope H and
F are endocytosed into the host cell, whereas viral N is
injected directly into the cytosol. Thus, antigens are in-
corporated into the host cell by endogenous and exog-
enous mechanisms and fit with a biological model
whereby measles-virus antigens are presented by both
the endogenous pathway, for the N protein, and the
exogenous pathway, for the H and F proteins.
Exceptions to these segregated classic pathways of an-
tigen processing and presentation have been observed in
the cellular response to measles and other antigens. En-
dogenous antigens, classically presented by class I mech-
anisms, can be presented by a class II mechanism, and
class II recognition of certain cytosolic peptides may re-
quire TAP1 function. Furthermore, both class I and II
molecules can complex with antigenic peptides in a pre-
Golgi compartment, into which class II–restricted anti-
gens are delivered by the TAP proteins (Nuchtern et al.
1990; Weiss and Bogen 1991; Malnati et al. 1992). Stim-
ulation of some class II–restricted T-cell clones depends
on a functional TAP transporter and on antigen pre-
sentation of soluble measles-virus antigens (Jacobson et
al. 1989; Long and Jacobson 1989; Nuchtern et al.
1990). This may, in part, account for the influence of
specific TAP alleles on phenotypic variations in antibody
titers in response to vaccination.
Measles virus may also directly affect expression of
class II antigens. HLA class II–restricted immune re-
sponses are required for normal immune handling of the
measles virus (Jacobson et al. 1984, 1988) and for vac-
cine-induced antibody response (Nuchtern et al. 1990;
Leopardi et al. 1993). The interplay of multiple genes
is likely to be similar to that seen in infections with other
viruses, such as HIV, where the cumulative contributions
of class I, class II, and TAP genes are important in reg-
ulating the response to infection (Kaslow et al. 1996).
The Influence of TAP and Other HLA Genes on
Antibody Response to Measles Vaccine
We use the response to live-measles vaccine as a model
with which to determine associations between the ex-
treme phenotypes of antibody nonresponse/hyperre-
sponse and specific HLA alleles, as well as associations
with HLA homozygosity. Our ongoing studies suggest
that seronegativity after vaccination clusters among re-
lated family members, that genetic polymorphisms
within the HLA significantly influence antibody levels,
and that HLA homozygosity is significantly associated
with nonresponse to immunization (Hayney et al. 1994,
1996, 1997; Poland et al. 1995).
We have examined measles-antibody levels as a func-
tion of different TAP alleles among schoolchildren who
had received measles vaccine 5–11 years earlier and who
were highly unlikely to have ever been exposed to the
wild virus (Hayney et al. 1995). We found a significant
association between antibody response and the variation
in amino acids found at position 665 of the TAP2 locus,
with hyperresponders dramatically more likely to be het-
erozygous at position 665 than nonresponders (P 
; Hayney et al. 1997). Hyperresponse was associ-.016
ated with an excess of TAP2 A/B genotypes, and non-
response with an excess of TAP2 A/C genotypes. These
data support the concepts that TAP-determined restric-
tion affects antibody response to measles-vaccine anti-
gens (Dimanlig et al. 1994; Hayney et al. 1997) and that
homozygosity, in and of itself, may impair antibody re-
sponse by restricting the diversity of peptides that can
be presented to T cells (Black et al. 1977; Black and
Salzano 1981; Hedrick 1990).
The linkage of TAP genes within the class II HLA
cluster raises the concern of the independent contribu-
tion of TAP and class II HLA genes to vaccine response.
Accordingly, we have used logistic regression analysis to
determine the independent effects of TAP2 position 665
and DRB1 homozygosity. Both TAP2- and DR-locus ho-
mozygosity were significantly more frequent among non-
responders than among hyperresponders ( forP  .015
TAP2; for DR). Nonresponders were five timesP  .011
more likely to be homozygous at TAP2 position 665
than were hyperresponders and 6.4 times more likely to
be DR homozygous. There were no significant interac-
tions between TAP2 and DR homozygosity, suggesting
an independent, additive effect of TAP2 homozygosity
at position 665 on antibody levels following measles
vaccination.
We have also examined the association between mea-
sles-antibody level and other class I and II HLA genes.
We found that the difference in distribution of class II
HLA-DR alleles among nonresponders and hyper-
responders was statistically significant (Poland et al.
1995; Hayney et al. 1996, and in press).Measles-vaccine
nonresponders lacked HLA DRB1*13 alleles signifi-
cantly more often than did hyperresponders or normal
controls, and nonresponders had an excess of DRB1*07
alleles. In addition, nonresponders had a significantly
increased frequency of DR homozygosity ( )P  .0001
and an excess of DQA1*05 alleles ( ), whereasP  .017
hyperresponders had an excess of DQA1*01 alleles
( ). The homozygosity rate for any DQA1 alleleP  .016
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was noted to be significantly higher among nonrespon-
ders than among hyperresponders (23.9% vs. 9.4%;
), and homozygous nonresponders were moreP  .037
likely to be DQA1*05 than was any other homozygote
genotype.
Similar analyses of the overall distribution of class I
HLA-A, -B, and -C alleles revealed significant differences
for the HLA-B alleles and HLA-C alleles (Poland et al.,
in press) but not for the HLA-A locus. In particular,
HLA-B7 and -B51 alleles were associated with hyper-
response, and B8, B13, B44, and C5 alleles with non-
response. We also found evidence of an allele dose
response of the B7 allele, with a B7 allele frequency of
6% for nonresponders, 15% for normal responders, and
22% for hyperresponders ( ). Finally, we alsoP  .0001
found that, for the HLA-B locus, nonresponders were
2.1 times more likely to be homozygous than were nor-
mal responders and 3.7 times more likely to be homo-
zygous than were hyperresponders ( ).P  .031
Future Prospects
The use of live viral vaccines (such as measles) as a
model for understanding host response to pathogens has
deepened our understanding of the role and importance
of HLA genes in influencing individual variability to an-
tigens. Moreover, this model has drawn our attention to
the role of the non-HLA genes influencing the antigen-
processing pathway genes. Our work has demonstrated
that HLA polymorphisms do not explain all of the in-
dividual variation in vaccine responsiveness. Rather, the
genetics implicates the antigen-processing pathway, par-
ticularly the TAP genes, as an important and independ-
ent contributor to individual variability in vaccine re-
sponsiveness. For this reason, the role of other genes
influencing antigen processing, such as the LMP andDM
genes, and genes producing chaperone proteins, heat
shock proteins, proteasomes, tapasins, and others (Gm
and Km allotypes) should be studied by models such as
this in order to determine their relative contributions to
individual host response to pathogens.
Vaccines may be used as a probe to understand the
observed variability in phenotypic responses such as an-
tibody response. Prospective studies of subjects with
knownHLA haplotypes have proven to be valuable tools
for identifying genetic influences on human immune re-
sponses. Additional studies exploring potential differ-
ences in antigen processing and presentation in subjects
with extreme phenotypes (i.e., nonresponse and hyper-
response) and differing HLA backgrounds will offer
uniquely important information. Fundamentally, such
studies should allow us to understand more fully why
some hosts apparently resist infection, some survive in-
fection, and some die. This work may allow the pro-
spective design of nearly universally immunogenic vac-
cines for a variety of pathogens and may lead to
strategies for circumventing nonresponse by designing
vaccines specifically for class I, class II, or combined
pathways of antigen processing. In principle, it should
be possible to design vaccines that take advantage of
individual differences in HLA haplotypes, antigen pres-
entation and processing, and other downstream events
in the host immune response.
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